Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating how well guselkumab works compared to risankizumab in people with moderately to severely active Crohns Disease, a long-term condition causing severe inflammation in the intestines. This Phase 3b study aims to compare the effectiveness and safety of these two treatments to better understand their impact on this condition. Participants will receive either guselkumab or risankizumab following specific dosing schedules. Those receiving guselkumab will get induction doses by subcutaneous injection at Weeks 0, 4, and 8, then maintenance doses every 4 weeks from Week 12 through Week 52. Participants in the risankizumab group will receive induction doses intravenously at Weeks 0, 4, and 8, followed by maintenance doses by subcutaneous injection every 8 weeks from Week 12 to Week 52. During the study, participants will be monitored for deep remission at Week 52, along with other outcomes like clinical remission, endoscopic response, and steroid-free remission. Safety will be assessed by tracking adverse events and lab test abnormalities up to Week 165. Follow-up will continue to evaluate long-term effects, with participant involvement lasting until study completion in 2030.
Actively Recruiting
Researchers are evaluating the clinical effectiveness and safety of icotrokinra in adults with moderately to severely active Crohns disease, a long-term condition causing serious inflammation in the intestines. The study is a Phase 2b3 randomized, double-blind, placebo-controlled trial aiming to better understand how well icotrokinra works in treating this condition. Participants will receive one of several oral treatments daily during an initial 12-week induction phase either one of two doses of icotrokinra or a matching placebo. After Week 12, their response status will guide further treatment. Those responding to icotrokinra may be randomized to maintenance doses for up to 40 weeks, with some eligible to join a long-term extension study. Placebo recipients who respond may continue placebo or switch to icotrokinra under specific conditions. Throughout the trial, participants will undergo regular assessments to monitor clinical response, remission, and endoscopic healing at Weeks 12 and 40. Safety will be closely followed up to four weeks after the last dose. The study measures various outcomes including patient-reported remission, inflammatory markers, quality of life, and fatigue. Total participation may extend up to several months depending on treatment phase and eligibility for long-term follow-up.
Actively Recruiting
Researchers are evaluating the efficacy and safety of tulisokibart in people with moderately to severely active Crohns disease. This program includes two separate studies Study 1, which involves both induction and maintenance treatment phases, and Study 2, which includes only the induction treatment phase. The main goals are to see if one or more doses of tulisokibart are better than placebo in achieving clinical remission according to specific Crohns Disease Activity Index scores or stool frequency and abdominal pain scores, and to assess endoscopic response at weeks 12 and 52 depending on the study and regulatory region. Participants receive tulisokibart either intravenously or subcutaneously at different dose levels depending on the study arm. Some receive a high dose induction followed by high or low dose maintenance, others receive low dose throughout, and some receive placebo. Extension arms allow participants who complete their original treatment to continue receiving high or low dose subcutaneous tulisokibart if they qualify. The study uses random assignment to treatment groups and is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the studies, participants undergo evaluations at specified weeks to measure clinical remission, clinical response, endoscopic response, and other outcomes such as fatigue and quality of life. Safety is monitored by tracking adverse events and discontinuations due to side effects. The overall participation may last up to 52 weeks for Study 1 and 12 weeks for Study 2, with assessments at multiple points to carefully observe treatment effects and safety.
Actively Recruiting
Psoriatic arthritis PsA is a type of arthritis that causes joint swelling and stiffness, often occurring in people with the skin condition psoriasis. This study aims to understand how long patients continue treatment and how effective risankizumab RZB is compared to other advanced treatments for PsA in everyday clinical settings. The study will take place outside the United States across about 15 countries, involving between 900 and 1200 adult participants. Participants will receive either risankizumab or other biologic disease-modifying antirheumatic drugs bDMARDs as prescribed by their doctors following local guidelines. Treatments will be given as part of regular medical care without additional interventions from the study. Participants will be followed and observed for 24 months during their routine clinical visits. During the study, participants will attend their usual medical appointments where doctors will monitor their treatment persistence and response. The main outcome measured is how many participants continue their prescribed treatment up to 24 months. There is no expected extra burden or additional procedures for participants beyond their standard care.
Actively Recruiting
Researchers are evaluating the safety and effects of arterial embolization using Lipiodol4 in patients with symptomatic hand osteoarthritis who have not responded to conventional treatments. This pilot study aims to understand the side effects and complications linked to the procedure, as well as its ability to reduce pain and improve hand function over a 6-month period. The study is sponsored by University Hospital, Grenoble, and includes patients aged 40 years and older with specific hand osteoarthritis symptoms and pain levels. Participants will undergo arterial embolization of the radial artery in the most painful hand using Lipiodol mixed with iodinated contrast medium. The procedure targets blood vessels supplying the affected joints. After treatment, patients will have regular follow-ups to monitor pain relief, swelling, joint function, and any side effects. Imaging studies such as ultrasound and arteriography will be used to assess changes in joint vascularization and damage over time. During the study, participants will be assessed for adverse events related to embolization using standard criteria from the time of treatment up to six months afterward. Pain intensity, joint swelling and tenderness, hand function, grip strength, and joint vascularization will be measured at baseline and at 1, 3, and 6 months post-treatment. Researchers will also monitor changes in the use of pain medications and hand microcirculation. The total participation duration is six months, with careful safety monitoring throughout.
Actively Recruiting
Researchers are evaluating whether combining mirikizumab with tirzepatide can reduce or eliminate symptoms of moderately to severely active ulcerative colitis UC and help participants lose at least 10% of their body weight. This phase 3b study focuses on adults with UC who are also obese or overweight, comparing treatment with mirikizumab plus tirzepatide against mirikizumab plus placebo. The study is sponsored by Eli Lilly and Company and aims to better understand treatment effects on UC symptoms and weight loss. Participants receive mirikizumab first by intravenous infusion, followed by subcutaneous injections of mirikizumab. They are randomly assigned to also receive either tirzepatide or a placebo via subcutaneous injection. Treatment lasts up to 52 weeks. The study is double-blinded, so neither participants nor researchers know who receives tirzepatide or placebo during the trial. Throughout the study, participants undergo regular monitoring including clinical assessments to evaluate remission and response of UC symptoms, endoscopic exams, and histologic evaluations. Researchers measure the percentage of participants who achieve both clinical remission and significant weight loss at week 52. The total participation time is up to 61 weeks, including screening and treatment. Safety and effectiveness are closely tracked during and after treatment.
Actively Recruiting
This trial investigates the safety and effectiveness of mirikizumab combined with tirzepatide versus mirikizumab with placebo in adults who have moderately to severely active Crohns disease along with obesity or overweight. The study is a phase 3b clinical trial and aims to assess how well these treatments work together to improve disease activity and reduce weight. Participants are randomly assigned to one of two groups one receives mirikizumab intravenously followed by subcutaneous administration along with tirzepatide given subcutaneously the other group receives mirikizumab in the same way but with a placebo injection instead of tirzepatide. Treatments are given according to a defined schedule over the course of the study, which lasts up to 61 weeks. Throughout the trial, participants undergo regular monitoring including clinical assessments for Crohns disease activity, endoscopic evaluations, and measurements of body weight. Researchers track outcomes like clinical remission, endoscopic remission, and weight loss at various time points, especially at Week 52. Safety and tolerability are also carefully observed during the study period that may extend up to 61 weeks.
Actively Recruiting
Researchers are evaluating the use of cryocompression compared to traditional icepacks to reduce inflammation and pain after total knee replacement surgery. This trial aims to assess whether cryocompression offers any additional benefit over icepacks in managing post-operative pain and healing. Previous studies have shown mixed results, and this study addresses uncertainties about cryocompressions effects on pain, mobility, wound healing, and opioid use. Participants will be randomly assigned to receive either cryocompression or icepacks immediately after surgery while staying in the hospital for 1 to 3 days. Both groups will use their assigned method continuously for 4 hours directly following surgery to reduce inflammation. The study compares these two non-invasive devices for post-operative care. Throughout the study and follow-up periods up to 9 months, participants will undergo assessments of pain, joint function, mobility, swelling, wound healing, blood loss, pain medication use, quality of sleep, and procedure safety. Data will be collected at specific time points including 48 hours, 1 month, 3 months, and 9 months after surgery to monitor recovery and outcomes carefully.
Actively Recruiting
Lateropulsion is a condition where a persons body orientation is tilted sideways relative to the vertical plane, often occurring after a stroke and leading to balance and walking difficulties. This study is focused on individuals who have had a first ischemic right hemisphere stroke and show moderate to severe lateropulsion, caused by a biased internal sense of verticality. The goal is to test whether a specific rehabilitation program can improve their perception of verticality and reduce lateropulsion. The rehabilitation program being evaluated lasts three weeks and includes 15 sessions of 30 minutes each. These sessions combine specialized physiotherapy exercises focused on vertical body orientation with exoskeleton-assisted balance and gait exercises using the Atalante device. Participants also continue conventional physiotherapy, occupational therapy, and other usual care throughout the study. The program aims to recalibrate the internal model of verticality through exercises such as standing, stepping, and walking in different directions, with or without visual cues, as well as tasks to increase body tilt awareness. Participants will be involved in daily visual verticality assessments and weekly evaluations of postural verticality, lateropulsion severity, balance, gait, and motor function over an eight-week period. Data on patient comfort and satisfaction with the exoskeleton sessions will also be collected. The study includes three participants who begin the intervention at staggered weeks to monitor progress and control for unrelated changes. The study aims to support improved balance and mobility recovery after stroke through this focused rehabilitation approach.
Actively Recruiting
This research aims to assess how a prosthetic foot with an adjustable heel height affects physical appearance and social participation in adults with major lower limb amputations. The study addresses the challenge that most prosthetic feet have a fixed heel height, which limits users to wearing shoes with the same heel height. Being able to choose different shoes freely is important for coping with physical disability and maintaining lifestyle preferences. Participants will use two types of prosthetic feet in a randomized order. One device is the Taleo Adjust foot, which features a hydraulic ankle allowing adjustable heel heights from 0 to 7 cm to match different shoe types without compromising walking quality. The other is the participants usual energy storage and return ESR foot with a fixed heel height. Each foot will be worn for 30 days, with participants either starting with the Taleo Adjust foot then switching to their usual foot, or vice versa. During the study, participants will be assessed using questionnaires and scales that measure appearance satisfaction, functional ability, psychosocial impact, device satisfaction, quality of life, mobility, and socket comfort. The primary outcome is the Prosthetic Evaluation Questionnaire - Appearance scale after 30 days of use for each foot. The study includes monitoring participant experiences and measuring how the adjustable heel foot influences daily activities and social participation over the two 30-day periods.
1-10 of 11
1